Potential of Antisense Technology in the Treatment of Immunological Disorders
Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. Th...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Krieg, Arthur M. [verfasserIn] Steinberg, Alfred D. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1995 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: BioDrugs - Berlin [u.a.] : Springer, 1997, 4(1995), 3 vom: Sept., Seite 169-179 |
|---|---|
| Übergeordnetes Werk: |
volume:4 ; year:1995 ; number:3 ; month:09 ; pages:169-179 |
| Links: |
|---|
| DOI / URN: |
10.1007/BF03259283 |
|---|
| Katalog-ID: |
SPR032978081 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR032978081 | ||
| 003 | DE-627 | ||
| 005 | 20230519224642.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1995 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/BF03259283 |2 doi | |
| 035 | |a (DE-627)SPR032978081 | ||
| 035 | |a (SPR)BF03259283-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Krieg, Arthur M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential of Antisense Technology in the Treatment of Immunological Disorders |
| 264 | 1 | |c 1995 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. The oligonucleotide can be directed at: (i) the gene itself (called the triplex approach), which typically targets regulatory sequences; (ii) messenger RNA after transcription, which targets the coding region; or (iii) the protein product. For intracellular modification of gene expression, the oligonucleotide must be able to enter the cell and the appropriate cellular compartment for action. Enclosing the oligonucleotide in liposomes improves cellular uptake and reduces the amount of oligonucleotide required for administration. The latter is important for reducing the possible toxic effects of large amounts of an oligonucleotide. Indeed, a therapeutic oligonucleotide preparation must be relatively specific and have a good therapeutic: toxic ratio in humans. To date, in vitro studies with antisense oligonucleotides against several interleukins, interleukin receptors, adhesion molecules and T cell receptors suggest that this approach is a promising one for immune-mediated diseases. The results of some in vivo studies are also encouraging, although it is not yet clear that the effects seen result from an antisense mechanism of action. This review examines both the possibilities and the problems of this approach to immunomodulation. | ||
| 650 | 4 | |a Adis International Limited |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antisense Oligonucleotide |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Phosphorothioate |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunological Disorder |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antisense Oligodeoxynucleotides |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Steinberg, Alfred D. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BioDrugs |d Berlin [u.a.] : Springer, 1997 |g 4(1995), 3 vom: Sept., Seite 169-179 |w (DE-627)327644672 |w (DE-600)2043743-2 |x 1179-190X |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:1995 |g number:3 |g month:09 |g pages:169-179 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF03259283 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 1995 |e 3 |c 09 |h 169-179 | ||
| author_variant |
a m k am amk a d s ad ads |
|---|---|
| matchkey_str |
article:1179190X:1995----::oetaoatsneehooynhtetetfmu |
| hierarchy_sort_str |
1995 |
| publishDate |
1995 |
| allfields |
10.1007/BF03259283 doi (DE-627)SPR032978081 (SPR)BF03259283-e DE-627 ger DE-627 rakwb eng 610 ASE Krieg, Arthur M. verfasserin aut Potential of Antisense Technology in the Treatment of Immunological Disorders 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. The oligonucleotide can be directed at: (i) the gene itself (called the triplex approach), which typically targets regulatory sequences; (ii) messenger RNA after transcription, which targets the coding region; or (iii) the protein product. For intracellular modification of gene expression, the oligonucleotide must be able to enter the cell and the appropriate cellular compartment for action. Enclosing the oligonucleotide in liposomes improves cellular uptake and reduces the amount of oligonucleotide required for administration. The latter is important for reducing the possible toxic effects of large amounts of an oligonucleotide. Indeed, a therapeutic oligonucleotide preparation must be relatively specific and have a good therapeutic: toxic ratio in humans. To date, in vitro studies with antisense oligonucleotides against several interleukins, interleukin receptors, adhesion molecules and T cell receptors suggest that this approach is a promising one for immune-mediated diseases. The results of some in vivo studies are also encouraging, although it is not yet clear that the effects seen result from an antisense mechanism of action. This review examines both the possibilities and the problems of this approach to immunomodulation. Adis International Limited (dpeaa)DE-He213 Antisense Oligonucleotide (dpeaa)DE-He213 Phosphorothioate (dpeaa)DE-He213 Immunological Disorder (dpeaa)DE-He213 Antisense Oligodeoxynucleotides (dpeaa)DE-He213 Steinberg, Alfred D. verfasserin aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 4(1995), 3 vom: Sept., Seite 169-179 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:4 year:1995 number:3 month:09 pages:169-179 https://dx.doi.org/10.1007/BF03259283 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 4 1995 3 09 169-179 |
| spelling |
10.1007/BF03259283 doi (DE-627)SPR032978081 (SPR)BF03259283-e DE-627 ger DE-627 rakwb eng 610 ASE Krieg, Arthur M. verfasserin aut Potential of Antisense Technology in the Treatment of Immunological Disorders 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. The oligonucleotide can be directed at: (i) the gene itself (called the triplex approach), which typically targets regulatory sequences; (ii) messenger RNA after transcription, which targets the coding region; or (iii) the protein product. For intracellular modification of gene expression, the oligonucleotide must be able to enter the cell and the appropriate cellular compartment for action. Enclosing the oligonucleotide in liposomes improves cellular uptake and reduces the amount of oligonucleotide required for administration. The latter is important for reducing the possible toxic effects of large amounts of an oligonucleotide. Indeed, a therapeutic oligonucleotide preparation must be relatively specific and have a good therapeutic: toxic ratio in humans. To date, in vitro studies with antisense oligonucleotides against several interleukins, interleukin receptors, adhesion molecules and T cell receptors suggest that this approach is a promising one for immune-mediated diseases. The results of some in vivo studies are also encouraging, although it is not yet clear that the effects seen result from an antisense mechanism of action. This review examines both the possibilities and the problems of this approach to immunomodulation. Adis International Limited (dpeaa)DE-He213 Antisense Oligonucleotide (dpeaa)DE-He213 Phosphorothioate (dpeaa)DE-He213 Immunological Disorder (dpeaa)DE-He213 Antisense Oligodeoxynucleotides (dpeaa)DE-He213 Steinberg, Alfred D. verfasserin aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 4(1995), 3 vom: Sept., Seite 169-179 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:4 year:1995 number:3 month:09 pages:169-179 https://dx.doi.org/10.1007/BF03259283 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 4 1995 3 09 169-179 |
| allfields_unstemmed |
10.1007/BF03259283 doi (DE-627)SPR032978081 (SPR)BF03259283-e DE-627 ger DE-627 rakwb eng 610 ASE Krieg, Arthur M. verfasserin aut Potential of Antisense Technology in the Treatment of Immunological Disorders 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. The oligonucleotide can be directed at: (i) the gene itself (called the triplex approach), which typically targets regulatory sequences; (ii) messenger RNA after transcription, which targets the coding region; or (iii) the protein product. For intracellular modification of gene expression, the oligonucleotide must be able to enter the cell and the appropriate cellular compartment for action. Enclosing the oligonucleotide in liposomes improves cellular uptake and reduces the amount of oligonucleotide required for administration. The latter is important for reducing the possible toxic effects of large amounts of an oligonucleotide. Indeed, a therapeutic oligonucleotide preparation must be relatively specific and have a good therapeutic: toxic ratio in humans. To date, in vitro studies with antisense oligonucleotides against several interleukins, interleukin receptors, adhesion molecules and T cell receptors suggest that this approach is a promising one for immune-mediated diseases. The results of some in vivo studies are also encouraging, although it is not yet clear that the effects seen result from an antisense mechanism of action. This review examines both the possibilities and the problems of this approach to immunomodulation. Adis International Limited (dpeaa)DE-He213 Antisense Oligonucleotide (dpeaa)DE-He213 Phosphorothioate (dpeaa)DE-He213 Immunological Disorder (dpeaa)DE-He213 Antisense Oligodeoxynucleotides (dpeaa)DE-He213 Steinberg, Alfred D. verfasserin aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 4(1995), 3 vom: Sept., Seite 169-179 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:4 year:1995 number:3 month:09 pages:169-179 https://dx.doi.org/10.1007/BF03259283 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 4 1995 3 09 169-179 |
| allfieldsGer |
10.1007/BF03259283 doi (DE-627)SPR032978081 (SPR)BF03259283-e DE-627 ger DE-627 rakwb eng 610 ASE Krieg, Arthur M. verfasserin aut Potential of Antisense Technology in the Treatment of Immunological Disorders 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. The oligonucleotide can be directed at: (i) the gene itself (called the triplex approach), which typically targets regulatory sequences; (ii) messenger RNA after transcription, which targets the coding region; or (iii) the protein product. For intracellular modification of gene expression, the oligonucleotide must be able to enter the cell and the appropriate cellular compartment for action. Enclosing the oligonucleotide in liposomes improves cellular uptake and reduces the amount of oligonucleotide required for administration. The latter is important for reducing the possible toxic effects of large amounts of an oligonucleotide. Indeed, a therapeutic oligonucleotide preparation must be relatively specific and have a good therapeutic: toxic ratio in humans. To date, in vitro studies with antisense oligonucleotides against several interleukins, interleukin receptors, adhesion molecules and T cell receptors suggest that this approach is a promising one for immune-mediated diseases. The results of some in vivo studies are also encouraging, although it is not yet clear that the effects seen result from an antisense mechanism of action. This review examines both the possibilities and the problems of this approach to immunomodulation. Adis International Limited (dpeaa)DE-He213 Antisense Oligonucleotide (dpeaa)DE-He213 Phosphorothioate (dpeaa)DE-He213 Immunological Disorder (dpeaa)DE-He213 Antisense Oligodeoxynucleotides (dpeaa)DE-He213 Steinberg, Alfred D. verfasserin aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 4(1995), 3 vom: Sept., Seite 169-179 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:4 year:1995 number:3 month:09 pages:169-179 https://dx.doi.org/10.1007/BF03259283 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 4 1995 3 09 169-179 |
| allfieldsSound |
10.1007/BF03259283 doi (DE-627)SPR032978081 (SPR)BF03259283-e DE-627 ger DE-627 rakwb eng 610 ASE Krieg, Arthur M. verfasserin aut Potential of Antisense Technology in the Treatment of Immunological Disorders 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. The oligonucleotide can be directed at: (i) the gene itself (called the triplex approach), which typically targets regulatory sequences; (ii) messenger RNA after transcription, which targets the coding region; or (iii) the protein product. For intracellular modification of gene expression, the oligonucleotide must be able to enter the cell and the appropriate cellular compartment for action. Enclosing the oligonucleotide in liposomes improves cellular uptake and reduces the amount of oligonucleotide required for administration. The latter is important for reducing the possible toxic effects of large amounts of an oligonucleotide. Indeed, a therapeutic oligonucleotide preparation must be relatively specific and have a good therapeutic: toxic ratio in humans. To date, in vitro studies with antisense oligonucleotides against several interleukins, interleukin receptors, adhesion molecules and T cell receptors suggest that this approach is a promising one for immune-mediated diseases. The results of some in vivo studies are also encouraging, although it is not yet clear that the effects seen result from an antisense mechanism of action. This review examines both the possibilities and the problems of this approach to immunomodulation. Adis International Limited (dpeaa)DE-He213 Antisense Oligonucleotide (dpeaa)DE-He213 Phosphorothioate (dpeaa)DE-He213 Immunological Disorder (dpeaa)DE-He213 Antisense Oligodeoxynucleotides (dpeaa)DE-He213 Steinberg, Alfred D. verfasserin aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 4(1995), 3 vom: Sept., Seite 169-179 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:4 year:1995 number:3 month:09 pages:169-179 https://dx.doi.org/10.1007/BF03259283 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 4 1995 3 09 169-179 |
| language |
English |
| source |
Enthalten in BioDrugs 4(1995), 3 vom: Sept., Seite 169-179 volume:4 year:1995 number:3 month:09 pages:169-179 |
| sourceStr |
Enthalten in BioDrugs 4(1995), 3 vom: Sept., Seite 169-179 volume:4 year:1995 number:3 month:09 pages:169-179 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Adis International Limited Antisense Oligonucleotide Phosphorothioate Immunological Disorder Antisense Oligodeoxynucleotides |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
BioDrugs |
| authorswithroles_txt_mv |
Krieg, Arthur M. @@aut@@ Steinberg, Alfred D. @@aut@@ |
| publishDateDaySort_date |
1995-09-01T00:00:00Z |
| hierarchy_top_id |
327644672 |
| dewey-sort |
3610 |
| id |
SPR032978081 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032978081</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519224642.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1995 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259283</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032978081</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259283-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Krieg, Arthur M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Potential of Antisense Technology in the Treatment of Immunological Disorders</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1995</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. The oligonucleotide can be directed at: (i) the gene itself (called the triplex approach), which typically targets regulatory sequences; (ii) messenger RNA after transcription, which targets the coding region; or (iii) the protein product. For intracellular modification of gene expression, the oligonucleotide must be able to enter the cell and the appropriate cellular compartment for action. Enclosing the oligonucleotide in liposomes improves cellular uptake and reduces the amount of oligonucleotide required for administration. The latter is important for reducing the possible toxic effects of large amounts of an oligonucleotide. Indeed, a therapeutic oligonucleotide preparation must be relatively specific and have a good therapeutic: toxic ratio in humans. To date, in vitro studies with antisense oligonucleotides against several interleukins, interleukin receptors, adhesion molecules and T cell receptors suggest that this approach is a promising one for immune-mediated diseases. The results of some in vivo studies are also encouraging, although it is not yet clear that the effects seen result from an antisense mechanism of action. This review examines both the possibilities and the problems of this approach to immunomodulation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antisense Oligonucleotide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Phosphorothioate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunological Disorder</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antisense Oligodeoxynucleotides</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Steinberg, Alfred D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BioDrugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1997</subfield><subfield code="g">4(1995), 3 vom: Sept., Seite 169-179</subfield><subfield code="w">(DE-627)327644672</subfield><subfield code="w">(DE-600)2043743-2</subfield><subfield code="x">1179-190X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:1995</subfield><subfield code="g">number:3</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:169-179</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259283</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">1995</subfield><subfield code="e">3</subfield><subfield code="c">09</subfield><subfield code="h">169-179</subfield></datafield></record></collection>
|
| author |
Krieg, Arthur M. |
| spellingShingle |
Krieg, Arthur M. ddc 610 misc Adis International Limited misc Antisense Oligonucleotide misc Phosphorothioate misc Immunological Disorder misc Antisense Oligodeoxynucleotides Potential of Antisense Technology in the Treatment of Immunological Disorders |
| authorStr |
Krieg, Arthur M. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)327644672 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-190X |
| topic_title |
610 ASE Potential of Antisense Technology in the Treatment of Immunological Disorders Adis International Limited (dpeaa)DE-He213 Antisense Oligonucleotide (dpeaa)DE-He213 Phosphorothioate (dpeaa)DE-He213 Immunological Disorder (dpeaa)DE-He213 Antisense Oligodeoxynucleotides (dpeaa)DE-He213 |
| topic |
ddc 610 misc Adis International Limited misc Antisense Oligonucleotide misc Phosphorothioate misc Immunological Disorder misc Antisense Oligodeoxynucleotides |
| topic_unstemmed |
ddc 610 misc Adis International Limited misc Antisense Oligonucleotide misc Phosphorothioate misc Immunological Disorder misc Antisense Oligodeoxynucleotides |
| topic_browse |
ddc 610 misc Adis International Limited misc Antisense Oligonucleotide misc Phosphorothioate misc Immunological Disorder misc Antisense Oligodeoxynucleotides |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
BioDrugs |
| hierarchy_parent_id |
327644672 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
BioDrugs |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)327644672 (DE-600)2043743-2 |
| title |
Potential of Antisense Technology in the Treatment of Immunological Disorders |
| ctrlnum |
(DE-627)SPR032978081 (SPR)BF03259283-e |
| title_full |
Potential of Antisense Technology in the Treatment of Immunological Disorders |
| author_sort |
Krieg, Arthur M. |
| journal |
BioDrugs |
| journalStr |
BioDrugs |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
1995 |
| contenttype_str_mv |
txt |
| container_start_page |
169 |
| author_browse |
Krieg, Arthur M. Steinberg, Alfred D. |
| container_volume |
4 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Krieg, Arthur M. |
| doi_str_mv |
10.1007/BF03259283 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
potential of antisense technology in the treatment of immunological disorders |
| title_auth |
Potential of Antisense Technology in the Treatment of Immunological Disorders |
| abstract |
Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. The oligonucleotide can be directed at: (i) the gene itself (called the triplex approach), which typically targets regulatory sequences; (ii) messenger RNA after transcription, which targets the coding region; or (iii) the protein product. For intracellular modification of gene expression, the oligonucleotide must be able to enter the cell and the appropriate cellular compartment for action. Enclosing the oligonucleotide in liposomes improves cellular uptake and reduces the amount of oligonucleotide required for administration. The latter is important for reducing the possible toxic effects of large amounts of an oligonucleotide. Indeed, a therapeutic oligonucleotide preparation must be relatively specific and have a good therapeutic: toxic ratio in humans. To date, in vitro studies with antisense oligonucleotides against several interleukins, interleukin receptors, adhesion molecules and T cell receptors suggest that this approach is a promising one for immune-mediated diseases. The results of some in vivo studies are also encouraging, although it is not yet clear that the effects seen result from an antisense mechanism of action. This review examines both the possibilities and the problems of this approach to immunomodulation. |
| abstractGer |
Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. The oligonucleotide can be directed at: (i) the gene itself (called the triplex approach), which typically targets regulatory sequences; (ii) messenger RNA after transcription, which targets the coding region; or (iii) the protein product. For intracellular modification of gene expression, the oligonucleotide must be able to enter the cell and the appropriate cellular compartment for action. Enclosing the oligonucleotide in liposomes improves cellular uptake and reduces the amount of oligonucleotide required for administration. The latter is important for reducing the possible toxic effects of large amounts of an oligonucleotide. Indeed, a therapeutic oligonucleotide preparation must be relatively specific and have a good therapeutic: toxic ratio in humans. To date, in vitro studies with antisense oligonucleotides against several interleukins, interleukin receptors, adhesion molecules and T cell receptors suggest that this approach is a promising one for immune-mediated diseases. The results of some in vivo studies are also encouraging, although it is not yet clear that the effects seen result from an antisense mechanism of action. This review examines both the possibilities and the problems of this approach to immunomodulation. |
| abstract_unstemmed |
Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. The oligonucleotide can be directed at: (i) the gene itself (called the triplex approach), which typically targets regulatory sequences; (ii) messenger RNA after transcription, which targets the coding region; or (iii) the protein product. For intracellular modification of gene expression, the oligonucleotide must be able to enter the cell and the appropriate cellular compartment for action. Enclosing the oligonucleotide in liposomes improves cellular uptake and reduces the amount of oligonucleotide required for administration. The latter is important for reducing the possible toxic effects of large amounts of an oligonucleotide. Indeed, a therapeutic oligonucleotide preparation must be relatively specific and have a good therapeutic: toxic ratio in humans. To date, in vitro studies with antisense oligonucleotides against several interleukins, interleukin receptors, adhesion molecules and T cell receptors suggest that this approach is a promising one for immune-mediated diseases. The results of some in vivo studies are also encouraging, although it is not yet clear that the effects seen result from an antisense mechanism of action. This review examines both the possibilities and the problems of this approach to immunomodulation. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE |
| container_issue |
3 |
| title_short |
Potential of Antisense Technology in the Treatment of Immunological Disorders |
| url |
https://dx.doi.org/10.1007/BF03259283 |
| remote_bool |
true |
| author2 |
Steinberg, Alfred D. |
| author2Str |
Steinberg, Alfred D. |
| ppnlink |
327644672 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/BF03259283 |
| up_date |
2024-07-03T15:50:10.167Z |
| _version_ |
1803573589619769344 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032978081</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519224642.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1995 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259283</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032978081</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259283-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Krieg, Arthur M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Potential of Antisense Technology in the Treatment of Immunological Disorders</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1995</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Oligonucleotide-mediated modification of gene expression offers the possibility of intervening therapeutically in a variety of immune-mediated conditions. This approach involves parenteral administration of a nuclease-resistant oligonucleotide specific for the sequence of a targeted gene. The oligonucleotide can be directed at: (i) the gene itself (called the triplex approach), which typically targets regulatory sequences; (ii) messenger RNA after transcription, which targets the coding region; or (iii) the protein product. For intracellular modification of gene expression, the oligonucleotide must be able to enter the cell and the appropriate cellular compartment for action. Enclosing the oligonucleotide in liposomes improves cellular uptake and reduces the amount of oligonucleotide required for administration. The latter is important for reducing the possible toxic effects of large amounts of an oligonucleotide. Indeed, a therapeutic oligonucleotide preparation must be relatively specific and have a good therapeutic: toxic ratio in humans. To date, in vitro studies with antisense oligonucleotides against several interleukins, interleukin receptors, adhesion molecules and T cell receptors suggest that this approach is a promising one for immune-mediated diseases. The results of some in vivo studies are also encouraging, although it is not yet clear that the effects seen result from an antisense mechanism of action. This review examines both the possibilities and the problems of this approach to immunomodulation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antisense Oligonucleotide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Phosphorothioate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunological Disorder</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antisense Oligodeoxynucleotides</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Steinberg, Alfred D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BioDrugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1997</subfield><subfield code="g">4(1995), 3 vom: Sept., Seite 169-179</subfield><subfield code="w">(DE-627)327644672</subfield><subfield code="w">(DE-600)2043743-2</subfield><subfield code="x">1179-190X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:1995</subfield><subfield code="g">number:3</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:169-179</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259283</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">1995</subfield><subfield code="e">3</subfield><subfield code="c">09</subfield><subfield code="h">169-179</subfield></datafield></record></collection>
|
| score |
7.400339 |